This company has been acquired
Resumen acción RETA
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de Reata Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$172.36 |
| 52 Week High | US$172.46 |
| 52 Week Low | US$21.83 |
| Beta | 1.42 |
| 1 Month Change | 2.05% |
| 3 Month Change | 70.82% |
| 1 Year Change | 581.80% |
| 3 Year Change | 76.92% |
| 5 Year Change | 125.48% |
| Change since IPO | 1,218.75% |
Noticias y actualizaciones recientes
Recent updates
Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation
May 10
FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug
Oct 13Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?
Oct 12Reata Pharmaceuticals Q2 2022 Earnings Preview
Aug 05We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth
Jun 22Reata Pharmaceuticals: Once Beaten, Twice Shy
Mar 28Reata's Advisory Committee Hiccup Ruins Its Future Prospects
Dec 31Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation
Dec 23Rentabilidad de los accionistas
| RETA | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 0.09% | -3.3% | -3.1% |
| 1Y | 581.8% | 11.3% | 20.9% |
Rentabilidad vs. Industria: RETA exceeded the US Pharmaceuticals industry which returned 10.9% over the past year.
Rentabilidad vs. Mercado: RETA exceeded the US Market which returned 15.1% over the past year.
Volatilidad de los precios
| RETA volatility | |
|---|---|
| RETA Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: RETA's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: RETA's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2002 | 322 | J. Huff | www.reatapharma.com |
Resumen de fundamentos de Reata Pharmaceuticals, Inc.
| Estadísticas fundamentales de RETA | |
|---|---|
| Capitalización bursátil | US$6.57b |
| Beneficios(TTM) | -US$87.62m |
| Ingresos (TTM) | US$23.48m |
279.7x
Ratio precio-ventas (PS)-74.9x
Ratio precio-beneficio (PE)¿Está RETA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de RETA | |
|---|---|
| Ingresos | US$23.48m |
| Coste de los ingresos | US$204.15m |
| Beneficio bruto | -US$180.67m |
| Otros gastos | -US$93.05m |
| Beneficios | -US$87.62m |
Últimos beneficios comunicados
Jun 30, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.30 |
| Margen bruto | -769.46% |
| Margen de beneficio neto | -373.18% |
| Ratio deuda/patrimonio | 83.8% |
¿Cómo se ha desempeñado RETA a largo plazo?
Ver rendimiento histórico y comparativa